Distinct genetic determinants and mechanisms of SARS-CoV-2 resistance to remdesivir
Laura J. Stevens(Vanderbilt University Medical Center), Mark R. Denison(Bipar), Jason K. Perry(Pulmatrix (United States)), Andrea J. Pruijssers(Vanderbilt Health), Jennifer Gribble(Vanderbilt University), Ralph S. Baric(University of North Carolina at Chapel Hill), Tomáš Cihlář(Gilead Sciences (United States)), Hery W. Lee(University of Alberta), Tia M. Hughes(Vanderbilt University Medical Center), Matthias Götte(University of Alberta), Egor P. Tchesnokov(University of Alberta), Xiaotao Lu(Vanderbilt University Medical Center), Danielle Porter(Gilead Sciences (United States)), Amelia S. George(Vanderbilt University Medical Center), Timothy P. Sheahan(University of North Carolina at Chapel Hill), Jiani Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Calvin J. Gordon(University of Alberta)
Cited by 6
Related Papers
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
|Nature Communications|2020|1.8k
Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group
|Journal of Virology|2013|1.3k
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
|Proceedings of the National Academy of Sciences|2017|1.2k